Regular ArticleOvarian Histopathology in Breast Cancer Patients Receiving Tamoxifen
References (20)
- et al.
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer
Am J Obstet Gynecol
(1996) - et al.
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature
Gynecol Oncol
(1994) - et al.
Endometriosis developing during tamoxifen therapy
Am J Obstet Gynecol
(1988) - et al.
Ovarian cancer and long-term tamoxifen in premenopausal women
Lancet
(1991) - et al.
Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen
Gynecol Oncol
(1996) - et al.
Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients
J Steroid Biochem Mol Biol
(1995) - et al.
Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth
Br J Cancer
(1994) - et al.
Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case
Obstet Gynecol
(1993) Tamoxifen and endometriosis. case report
Br J Obstet Gynecol
(1990)
There are more references available in the full text version of this article.
Cited by (14)
Medical treatments of presumed benign ovarian tumors
2013, Journal de Gynecologie Obstetrique et Biologie de la ReproductionTamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
2009, Gynecologic OncologyCitation Excerpt :Cohen et al. reported an incidence of ovarian cancers of 5.7% (10/175) in post-menopausal breast cancer patients treated with tamoxifen, a rate 4–5 times the expected [21]. However, this was not confirmed in several additional studies, among them the National Surgical Adjuvant Breast and Bowel Project P-1 Study in which patients were randomized to tamoxifen or placebo [6,22,23] All incident cancers were noted and no difference in the incidence of ovarian cancer was found. Our study is the first to evaluate the risk of ovarian cancer with tamoxifen treatment in BRCA1 mutation carriers.
Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses
2006, Molecular and Cellular EndocrinologySex hormones and related compounds, including hormonal contraceptives
2001, Side Effects of Drugs AnnualSuccessful management of an ovarian enlargement resembling ovarian hyperstimulation in a premenopausal breast cancer patient receiving tamoxifen with cotreatment of GnRH-agonist
2001, European Journal of Obstetrics Gynecology and Reproductive Biology
Copyright © 1999 Academic Press. All rights reserved.